About prime medicine inc - PRME
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
PRME At a Glance
Prime Medicine, Inc.
60 First Street
Cambridge, Massachusetts 02141-2300
| Phone | 1-617-465-0013 | Revenue | 4.63M | |
| Industry | Biotechnology | Net Income | -201,142,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 55.28% | |
| Fiscal Year-end | 12 / 2026 | Employees | 146 | |
| View SEC Filings |
PRME Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 111.44 |
| Price to Book Ratio | 5.182 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.263 |
| Enterprise Value to Sales | 98.217 |
| Total Debt to Enterprise Value | 0.256 |
PRME Efficiency
| Revenue/Employee | 31,726.027 |
| Income Per Employee | -1,377,684.932 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.008 |
PRME Liquidity
| Current Ratio | 4.841 |
| Quick Ratio | 4.841 |
| Cash Ratio | 4.745 |
PRME Profitability
| Gross Margin | -58.053 |
| Operating Margin | -4,498.057 |
| Pretax Margin | -4,342.444 |
| Net Margin | -4,342.444 |
| Return on Assets | -36.347 |
| Return on Equity | -146.81 |
| Return on Total Capital | -84.765 |
| Return on Invested Capital | -95.899 |
PRME Capital Structure
| Total Debt to Total Equity | 96.326 |
| Total Debt to Total Capital | 49.064 |
| Total Debt to Total Assets | 18.881 |
| Long-Term Debt to Equity | 89.594 |
| Long-Term Debt to Total Capital | 45.635 |